慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的治疗进展  

Progress in the treatment of chronic lymphoblastic leukemia/small lymphocytic lymphoma

作　　者：谭巧云 文秋月 张利玲[1] Tan Qiaoyun;Wen Qiuyue;Zhang Liling(Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology/Hubei Key Laboratory of Precision Radiation Oncology/lnstitute of Radiation Oncology Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院肿瘤中心、湖北省精准放射肿瘤学重点实验室、华中科技大学同济医学院附属协和医院肿瘤放射研究所,武汉430022

出　　处：《中国肿瘤临床与康复》2023年第4期230-237,共8页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)是一种慢性B淋巴细胞增殖性疾病。随着人们对CLL/SLL在临床和分子水平上的深入了解,CLL/SLL的新型治疗方案也不断涌现,包括靶向治疗、嵌合抗原受体T细胞免疫疗法和异基因造血干细胞移植。其中靶向治疗包括:布鲁顿氏酪氨酸激酶抑制剂、磷脂酰肌醇3激酶抑制剂、B细胞淋巴瘤因子2抑制剂和蛋白激酶Cβ抑制剂。除新型药物的不断涌现,各疗法之间的联合治疗和对固定疗程的探索在CLL/SLL的治疗中也备受关注。文章结合相关文献对CLL/SLL的最新治疗进展进行总结。Chronic lymphoblastic leukemia(CLL)/small lymphocytic lymphoma(SLL)is a chronic B lymphocyte proliferative disease.With the in-depth understanding of the clinical and molecular level of CLL/SLL,new treatments for CLL/SLL continue to emerge,including targeted therapy,chimeric antigen receptor T-cell immunotherapy and allogeneic hematopoietic stem cell transplantation.Targeted therapy includes Bruton's tyrosine kinase inhibitors,phosphoinositide 3 kinase inhibitors,B cell lymphoma 2 inhibitors,and protein kinase Cβinhibitors.In addition to the continued emergence of novel drugs,combination therapy and the exploration of treatment duration are of increasing interest in CLL/SLL.This article will comprehensively describe the latest treatment progress of CLL/SLL combined with the relevant literature.

关 键 词：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 治疗 临床疗效 

分 类 号：R733.71[医药卫生—肿瘤]